Aprepitant for erlotinib-induced pruritus

New England Journal of Medicine

Volumn 363, Issue 17, 2010, Pages 1680-1681

  Levêque, Dominique ^a  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

APREPITANT; CYTOCHROME P450 3A4; ERLOTINIB; MIDAZOLAM; ANTINEOPLASTIC AGENT; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A INHIBITOR; MORPHOLINE DERIVATIVE; NEUROKININ 1 RECEPTOR ANTAGONIST; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

CANCER PATIENT; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG METABOLISM; HUMAN; INTESTINE CELL; LETTER; LIVER CELL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PRURITUS; AREA UNDER THE CURVE; CHEMICALLY INDUCED; DRUG ADMINISTRATION; DRUG INTERACTION; OFF LABEL DRUG USE;

ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CYTOCHROME P-450 CYP3A INHIBITORS; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; HUMANS; MORPHOLINES; NEUROKININ-1 RECEPTOR ANTAGONISTS; OFF-LABEL USE; PROTEIN KINASE INHIBITORS; PRURITUS; QUINAZOLINES;

EID: 77958612727     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1009698     Document Type: Letter

References (4)

1. Vincenzi B, Tonini G, Santini D. Aprepitant for erlotinib-induced pruritus. N Engl J Med 2010;363:397-8.
2. Frohna P, Lu J, Eppler S, et al. Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects. J Clin Pharmacol 2006;46:282-90.
3. Rakhit A, Pantze MP, Fettner S, et al. The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYPTM) predicts in vivo metabolic inhibition. Eur J Clin Pharmacol 2008;64:31-41.
4. Majumdar AK, McCrea JB, Panebianco DL, et al. Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe. Clin Pharmacol Ther 2003;74:150-6.